Cytokinetics Stock Performance

CYTK
 Stock
  

USD 41.00  2.90  6.61%   

Cytokinetics has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.22, which signifies a somewhat significant risk relative to the market. Let's try to break down what Cytokinetics's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cytokinetics will likely underperform. Although it is important to respect Cytokinetics historical returns, it is better to be realistic regarding the information on the equity's current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Cytokinetics technical indicators, you can presently evaluate if the expected return of 0.16% will be sustainable into the future. Cytokinetics right now shows a risk of 5.15%. Please confirm Cytokinetics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Cytokinetics will be following its price patterns.
  
Refresh
Cytokinetics Performance
2 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Cytokinetics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Cytokinetics may actually be approaching a critical reversion point that can send shares even higher in August 2022. ...more

Structure and Payout Changes

Last Split Factor
1:6
Last Split Date
2013-06-25

Cytokinetics Price Channel

Quick Ratio7.28
Fifty Two Week Low17.72
Target High Price75.00
Fifty Two Week High49.41
Target Low Price46.00

Cytokinetics Relative Risk vs. Return Landscape

If you would invest  4,319  in Cytokinetics on April 7, 2022 and sell it today you would earn a total of  71.00  from holding Cytokinetics or generate 1.64% return on investment over 90 days. Cytokinetics is currently generating 0.1609% in daily expected returns and assumes 5.1453% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Cytokinetics, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Cytokinetics is expected to generate 3.5 times more return on investment than the market. However, the company is 3.5 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The DOW is currently generating roughly -0.12 per unit of risk.

Cytokinetics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytokinetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cytokinetics, and traders can use it to determine the average amount a Cytokinetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0313

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsCYTK
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns
Estimated Market Risk
 5.15
  actual daily
 
 44 %
of total potential
 
4444
Expected Return
 0.16
  actual daily
 
 3 %
of total potential
 
33
Risk-Adjusted Return
 0.03
  actual daily
 
 2 %
of total potential
 
22
Based on monthly moving average Cytokinetics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytokinetics by adding it to a well-diversified portfolio.

About Cytokinetics Performance

To evaluate Cytokinetics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Cytokinetics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Cytokinetics Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Cytokinetics stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Cytokinetics's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Investment(58.61) (63.24) 
Return on Average Assets(0.31) (0.33) 
Return on Average Equity(1.49) (1.53) 
Return on Invested Capital(0.24) (0.27) 
Return on Sales(2.82) (3.05) 
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Things to note about Cytokinetics

Checking the ongoing alerts about Cytokinetics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cytokinetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Cytokinetics Alerts

Equity Alerts and Improvement Suggestions

Cytokinetics has very high historical volatility over the last 90 days
Cytokinetics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 70.43 M. Net Loss for the year was (215.31 M) with loss before overhead, payroll, taxes, and interest of (89.51 M).
Cytokinetics currently holds about 471.64 M in cash with (142.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.56.
Cytokinetics has a poor financial position based on the latest SEC disclosures
Latest headline from www.bdtonline.com: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Bluefield Daily Telegraph
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.5 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.